Category Archives: News

DURHAM, N.C., NOVEMBER 14, 2017 — By 2030, it’s estimated that 75 million people will suffer from some form of dementia, with the cost of patient care reaching $2 trillion annually. By far the most common form of dementia is Alzheimer’s disease, the target of 143 drugs now in development. Premier Research will examine challengesRead more

DURHAM, N.C., November 1, 2017 — Finding the optimal dose, dosing regimen — and, in a growing number of trials, the right combination treatment partner — is essential to developing an oncology therapeutic. Early-phase oncology trial designs must take into account the latest information about emerging therapies, biomarkers, and trial methodology, along with evolving regulations,Read more

DURHAM, N.C., OCTOBER 20, 2017 — Premier Research’s head of patient engagement will address patients’ emerging role in the development of novel drugs October 23 at the Cambridge Rare Disease Network Summit in Cambridge, U.K. Juliet Moritz, the CRO’s Executive Director for Patient Engagement and Strategic Development, will discuss how patient advocacy groups are greatlyRead more

DURHAM, N.C., OCTOBER 19, 2017 — Premier Research’s head of patient engagement will address patients’ emerging role in the development of novel drugs October 23 at the Cambridge Rare Disease Network Summit in Cambridge, U.K. Juliet Moritz, the CRO’s Executive Director for Patient Engagement and Strategic Development, will discuss how patient advocacy groups are greatlyRead more

DURHAM, N.C., OCTOBER 17, 2017 — Patients with Wolf-Hirschhorn syndrome, a congenital malformation disorder caused by variably sized chromosomal deletions, may have fewer motor-skill and communicative impairments than commonly believed. That’s the conclusion of an article in the European Journal of Medical Genetics co-authored by an expert at Premier Research. Dr. Susanne Schmidt, Premier ResearchRead more

DURHAM, N.C., SEPTEMBER 25, 2017 — Premier Research’s Chief Medical Officer will discuss development of immuno-oncology molecules at Outsourcing in Clinical Trials Southern California, September 27-28 in La Jolla. Dr. Colin Hayward will address strategic and practical considerations for molecule development on the opening day of the annual gathering of pharma, biotech, and medical device leaders.Read more

DURHAM, N.C., September 13, 2017 — Premier Research’s head of patient engagement will address patients’ emerging role in the development of novel drugs at the Global Genes RARE Patient Advocacy Summit in Irvine, California. Juliet Moritz, the CRO’s Executive Director for Patient Engagement and Strategic Development, will join Alvin Shih, CEO of the biotech companyRead more

 DURHAM, N.C., September 12, 2017 — Osteoarthritis is the leading cause of disability due to pain and the most common form of arthritis, afflicting an estimated 237 million people worldwide. At a live webinar on Tuesday, September 19 (11am EDT / 4pm BST / 5pm CEST), Premier Research will examine new approaches to one ofRead more

DURHAM, N.C., SEPTEMBER 5, 2017 — Sponsors and CROs can forge stronger relationships by pursuing long-term partnerships that value collaboration over transactions. Premier Research’s top neuroscientist will discuss how when she hosts a session at Outsourcing Clinical Trials New England in Boston. Krista Armstrong, Vice President and Head of Neuroscience, will describe best practices forRead more

DURHAM, N.C., September 5, 2017 — Defining efficacy and safety endpoints that are scientifically measurable, objective, and valid is a critical challenge for developers of medical devices. At a live webinar on Tuesday, September 12 (11am EDT / 4pm BST / 5pm CEST), Premier Research will examine how clinical endpoint committees play an ever-larger roleRead more

Phone Us Now
Email Us Now